These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29369455)

  • 1. Development and validation of the Cholinergic Urticaria Quality-of-Life Questionnaire (CholU-QoL).
    Ruft J; Asady A; Staubach P; Casale T; Sussmann G; Zuberbier T; Maurer M; Weller K; Altrichter S
    Clin Exp Allergy; 2018 Apr; 48(4):433-444. PubMed ID: 29369455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of the mastocytosis quality of life questionnaire: MC-QoL.
    Siebenhaar F; von Tschirnhaus E; Hartmann K; Rabenhorst A; Staubach P; Peveling-Oberhag A; Wagner N; Martus P; Carter MC; Metcalfe DD; Church MK; Maurer M; Weller K
    Allergy; 2016 Jun; 71(6):869-77. PubMed ID: 26797792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial.
    Grekowitz E; Metz M; Altrichter S; Bauer A; Brockow K; Heine G; Lionnet L; Saday KK; Hultsch T; Søerensen OE; Maurer M
    Br J Dermatol; 2024 May; 190(6):825-835. PubMed ID: 38308655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atopic predisposition in cholinergic urticaria patients and its implications.
    Altrichter S; Koch K; Church MK; Maurer M
    J Eur Acad Dermatol Venereol; 2016 Dec; 30(12):2060-2065. PubMed ID: 27324252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and construct validation of the angioedema quality of life questionnaire.
    Weller K; Groffik A; Magerl M; Tohme N; Martus P; Krause K; Metz M; Staubach P; Maurer M
    Allergy; 2012 Oct; 67(10):1289-98. PubMed ID: 22913638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the cholinergic urticaria activity score, CholUAS.
    Schnarkowski P; Salameh P; Grekowitz E; Terhorst D; Maurer M; Weller K; Altrichter S
    J Allergy Clin Immunol Pract; 2024 Oct; ():. PubMed ID: 39424194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholinergic urticaria patients of different age groups have distinct features.
    Asady A; Ruft J; Ellrich A; Hawro T; Maurer M; Altrichter S
    Clin Exp Allergy; 2017 Dec; 47(12):1609-1614. PubMed ID: 28873238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conceptualization, development and validation of T-QoL
    Basra MKA; Salek MS; Fenech D; Finlay AY
    Br J Dermatol; 2018 Jan; 178(1):161-175. PubMed ID: 28762236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of the mastocytosis activity score.
    Siebenhaar F; Sander B; Ho LHT; Ellrich A; Maurer M; Weller K
    Allergy; 2018 Jul; 73(7):1489-1496. PubMed ID: 29405310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD).
    Whalley D; McKenna SP; Dewar AL; Erdman RA; Kohlmann T; Niero M; Cook SA; Crickx B; Herdman MJ; Frech F; Van Assche D
    Br J Dermatol; 2004 Feb; 150(2):274-83. PubMed ID: 14996098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease Impact, Diagnostic Delay, and Unmet Medical Needs of Patients With Cholinergic Urticaria in German-Speaking Countries.
    Altrichter S; Mellerowicz E; Terhorst-Molawi D; Grekowitz E; Weller K; Maurer M
    Front Allergy; 2022; 3():867227. PubMed ID: 35769577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired sweating in patients with cholinergic urticaria is linked to low expression of acetylcholine receptor CHRM3 and acetylcholine esterase in sweat glands.
    Wang Y; Scheffel J; Vera CA; Liu W; Günzel D; Terhorst-Molawi D; Maurer M; Altrichter S
    Front Immunol; 2022; 13():955161. PubMed ID: 35967390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a condition-specific measure for chronic periodontitis: Oral health impact profile for chronic periodontitis.
    He S; Wang J; Wei S; Ji P
    J Clin Periodontol; 2017 Jun; 44(6):591-600. PubMed ID: 28278366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life treatment of patients with cholinergic urticaria in German-speaking countries.
    Mellerowicz E; Weller K; Zuberbier T; Maurer M; Altrichter S
    J Dtsch Dermatol Ges; 2019 Nov; 17(11):1141-1147. PubMed ID: 31765087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development, validation, and initial results of the Angioedema Activity Score.
    Weller K; Groffik A; Magerl M; Tohme N; Martus P; Krause K; Metz M; Staubach P; Maurer M
    Allergy; 2013 Sep; 68(9):1185-92. PubMed ID: 23919330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials.
    McKenna SP; Cook SA; Whalley D; Doward LC; Richards HL; Griffiths CE; Van Assche D
    Br J Dermatol; 2003 Aug; 149(2):323-31. PubMed ID: 12932239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.
    Ferner RE; Thomas M; Mercer G; Williams V; Leschziner GD; Afridi SK; Golding JF
    Health Qual Life Outcomes; 2017 Feb; 15(1):34. PubMed ID: 28193237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a standardized pulse-controlled ergometry test for diagnosing and investigating cholinergic urticaria.
    Altrichter S; Salow J; Ardelean E; Church MK; Werner A; Maurer M
    J Dermatol Sci; 2014 Aug; 75(2):88-93. PubMed ID: 24837213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control.
    Weller K; Groffik A; Church MK; Hawro T; Krause K; Metz M; Martus P; Casale TB; Staubach P; Maurer M
    J Allergy Clin Immunol; 2014 May; 133(5):1365-72, 1372.e1-6. PubMed ID: 24522090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire.
    Sebaratnam DF; Hanna AM; Chee SN; Frew JW; Venugopal SS; Daniel BS; Martin LK; Rhodes LM; Tan JC; Wang CQ; Welsh B; Nijsten T; Murrell DF
    JAMA Dermatol; 2013 Oct; 149(10):1186-91. PubMed ID: 23925444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.